Würzburg-based T-CURX today announces the first closing of a €17.7 million Series A to accelerate clinical development of T-CURX non-viral clinical CAR-T therapies in AML and solid tumor indications, as well as advancing T-CURX proprietary non-viral technologies for in vivo CAR-T generation.
The Series A syndicate was led by BiomedVC and included Bayern Kapital, HighLight Capital (HLC), and i&iBio Fund, as additional investors along with existing and new individual investors.
Ulf Grawunder, PhD, co-founder and CEO of T-CURX, says: “I am very excited that T-CURX attracted such a high-profile, international investor’s syndicate, led by BiomedVC, for financing T-CURX`s non-clinical and clinical CAR-T technologies and CAR-T pipeline programs, respectively. It is a testament of the high quality of T-CURX data and the promise of our non-clinical and clinical non-viral CAR-T pipeline in AML & CLL and solid tumor indications going after novel targets. It also highlights the high value of our unique approach to leverage non-viral CAR-vector and LNP technologies for highly economical and scalable in vivo CAR-T generation, in order to ‘democratise’ CAR-T therapies for patients globally.”
In 2025, funding activity points to steady but selective investment activity across Europe’s oncology and immuno-oncology landscape, providing context for T-CURX’s Series A.
Alongside the German CAR-T developer, several other cancer-focused companies have secured funding this year. In Switzerland, Hedera Dx raised €15 million in a Series A to scale its precision oncology and diagnostics platform aimed at improving access to targeted cancer therapies. Finland-based TILT Biotherapeutics secured €22.6 million in a Series B to advance clinical development of its immuno-oncology candidates for solid tumours, while Dutch startup BIMINI Biotech closed a €3 million Seed round to progress small-molecule therapies for haematological cancers.
Taken together, these rounds represent approximately €58 million in disclosed funding moving through the European cancer and immunotherapy sector in 2025. Within this cohort, T-CURX’s Series A ranks among the larger early-stage raises and stands out for its focus on non-viral CAR-T technologies developed in Germany.
Aristotelis Nastos, PhD, Managing Partner and investment director at lead-investor BiomedVC adds: “I am thrilled about leading a highly dedicated international syndicate of early-stage investors from Europe and Asia in this Series A financing for T-CURX. We were deeply impressed by the data on non-viral CAR-T product and technology development at T-CURX, the track-record and experience of T-CURX Founder’s and Management team and the promise of T-CURX non-viral CAR-T technologies hold for making CAR-T therapies accessible and affordable for many cancer patients globally.
“We are very much looking forward to support T-CURX to achieve all of their therapeutic and commercial ambitions.”
Founded in 2017, T-CURX is a German BioTech company spun-out of the laboratory of its co-founder, Prof. Michael Hudecek, University of Würzburg, who is a European KOL and pioneer in the development and clinical translation of non-viral CAR-T cell therapies to target various types of cancer.
Their mission is to bring next-generation CAR-T cell therapies manufactured with cost-effective and highly scalable non-viral CAR-T cell technologies to more cancer patients in need of more effective cancer therapies.
T-CURX leverages a portfolio of proprietary non-viral CAR-T technologies for scalable and cost-effective CAR-T manufacturing based on virus-free, Sleeping-beauty transposon gene transfer into patient’s T cells.
Read the orginal article: https://www.eu-startups.com/2025/12/german-startup-t-curx-secures-e17-7-million-to-support-development-of-new-cancer-treatments/
